Education
About Us
Working with TipRanks
Follow Us
Theratechnologies Inc (THTX)
NASDAQ:THTX
THTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.08 - $2.18
Previous CloseN/A
Volume43.44K
Average Volume (3M)273.84K
Market Cap
$71.16M
Enterprise Value$110.99M
Total Cash (Recent Filing)$5.90M
Total Debt (Recent Filing)$45.61M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Apr 09, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding45,980,020
10 Day Avg. Volume575,188
30 Day Avg. Volume273,839
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)-80.00
P/FCF Ratio1.70
Enterprise Value/Market Cap1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.70
Enterprise Value/Ebitda19.48
Forecast
1Y Price Target
$3.80Price Target Upside104.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Theratechnologies News
PremiumCompany Announcements
Theratechnologies Gains FDA Nod for Enhanced HIV Treatment
PremiumCompany Announcements
Theratechnologies’ Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Theratechnologies Reports Strong Fiscal 2024 PerformancePremiumCompany Announcements
Theratechnologies Achieves Record Financial Results and Secures Future Growth---
Bulls Say, Bears Say
Bulls Say
Credit FacilitiesNew credit facilities of up to $75M secured provide Theratechnologies with a critical safety net to support operations and commercialization efforts.
FDA ApprovalFDA approval for the F8 formulation of tesamorelin, marketed as EGRIFTA WR, is expected to maintain medium- to long-term growth for the tesamorelin franchise.
Financial PositionTHTX is on solid financial footing with a positive long-term growth trajectory due to its current HIV franchise.
Bears Say
Competitive PressuresTROGARZO sales decreased 22.9% year-over-year due to a loss of market share secondary to competitive pressures.
Manufacturing DelaysThere will be a delay in the adoption of the new EGRIFTA WR formulation by payors, meaning the full impact is unlikely to be realized soon.
Supply Chain RisksThere is a risk of a temporary supply disruption for EGRIFTA SV due to an unexpected voluntary shutdown of the contract manufacturer's facility following an FDA inspection.
---
Ownership Overview
―
Insiders
0.06% Mutual Funds
23.44% Other Institutional Investors
76.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
THTX FAQ
What was Theratechnologies Inc’s price range in the past 12 months?
Theratechnologies Inc lowest stock price was $1.08 and its highest was $2.18 in the past 12 months.
What is Theratechnologies Inc’s market cap?
Theratechnologies Inc’s market cap is $71.16M.
When is Theratechnologies Inc’s upcoming earnings report date?
Theratechnologies Inc’s upcoming earnings report date is Apr 09, 2025 which is in 12 days.
How were Theratechnologies Inc’s earnings last quarter?
Theratechnologies Inc released its earnings results on Feb 26, 2025. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of $0.05 by -$0.21.
Is Theratechnologies Inc overvalued?
According to Wall Street analysts Theratechnologies Inc’s price is currently Undervalued.
Does Theratechnologies Inc pay dividends?
Theratechnologies Inc does not currently pay dividends.
What is Theratechnologies Inc’s EPS estimate?
Theratechnologies Inc’s EPS estimate is 0.03.
How many shares outstanding does Theratechnologies Inc have?
Theratechnologies Inc has 45,980,020 shares outstanding.
What happened to Theratechnologies Inc’s price movement after its last earnings report?
Theratechnologies Inc reported an EPS of -$0.16 in its last earnings report, missing expectations of $0.05. Following the earnings report the stock price went down -12.088%.
Which hedge fund is a major shareholder of Theratechnologies Inc?
Currently, no hedge funds are holding shares in THTX
---
Theratechnologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.80 (104.30% Upside)
$3.80 (104.30% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 11.6%
Last 30 Days ▼ 11.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.41%
Trailing 12-Months
Company Description
Theratechnologies Inc
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
---
THTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Theratechnologies reported a strong fiscal year with significant improvement in adjusted EBITDA and continued growth in EGRIFTA SV sales, supported by new strategic partnerships and credit facilities. However, challenges remain with declining TRYNGOLZA sales, increased G&A expenses, and high net finance costs, balanced by efforts to address these issues.Read More>---
THTX Stock 12 Month Forecast
Average Price Target
$3.80
▲(104.30% Upside)
Technical Analysis
Oncolytics Biotech
―
Bausch Health Companies
―
Neo Performance Materials Inc
―
HLS Therapeutics Inc
―
Premier Health of America Inc
―
Best Analysts Covering THTX
1 Year
1 Year Success Rate
8/15 ratings generated profit
1 Year Average Return
+5.87%
reiterated a buy rating last month
Copying Andre Uddin's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +5.87% per trade.
---